Squarepoint Ops LLC Takes Position in FibroGen, Inc. (NASDAQ:FGEN)

Squarepoint Ops LLC acquired a new stake in FibroGen, Inc. (NASDAQ:FGEN) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 386,752 shares of the biopharmaceutical company’s stock, valued at approximately $205,000. Squarepoint Ops LLC owned 0.38% of FibroGen as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Two Sigma Investments LP increased its holdings in FibroGen by 19.6% in the fourth quarter. Two Sigma Investments LP now owns 604,421 shares of the biopharmaceutical company’s stock valued at $320,000 after buying an additional 98,888 shares in the last quarter. Two Sigma Advisers LP raised its position in shares of FibroGen by 18.3% in the fourth quarter. Two Sigma Advisers LP now owns 878,400 shares of the biopharmaceutical company’s stock valued at $465,000 after buying an additional 135,600 shares during the last quarter. Two Sigma Securities LLC purchased a new position in shares of FibroGen during the 4th quarter worth $27,000. XTX Topco Ltd increased its stake in FibroGen by 423.8% in the fourth quarter. XTX Topco Ltd now owns 96,025 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 77,693 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in FibroGen by 80.4% during the fourth quarter. Renaissance Technologies LLC now owns 1,358,712 shares of the biopharmaceutical company’s stock worth $719,000 after buying an additional 605,572 shares during the period. Institutional investors and hedge funds own 72.71% of the company’s stock.

Insider Transactions at FibroGen

In other FibroGen news, CEO Thane Wettig bought 145,000 shares of the stock in a transaction on Monday, March 24th. The stock was purchased at an average price of $0.35 per share, for a total transaction of $50,750.00. Following the completion of the purchase, the chief executive officer now directly owns 543,329 shares in the company, valued at approximately $190,165.15. This trade represents a 36.40% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director James A. Schoeneck bought 250,000 shares of the company’s stock in a transaction on Thursday, March 20th. The shares were acquired at an average cost of $0.35 per share, for a total transaction of $87,500.00. Following the completion of the acquisition, the director now directly owns 323,722 shares of the company’s stock, valued at $113,302.70. This trade represents a 339.11% increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 3.07% of the company’s stock.

FibroGen Stock Performance

Shares of NASDAQ FGEN opened at $0.31 on Monday. The firm has a market cap of $31.66 million, a price-to-earnings ratio of -0.25 and a beta of 0.83. FibroGen, Inc. has a 1 year low of $0.18 and a 1 year high of $1.53. The stock’s 50-day simple moving average is $0.30 and its 200-day simple moving average is $0.41.

FibroGen (NASDAQ:FGEN) last released its earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.19). The firm had revenue of $2.70 million during the quarter, compared to the consensus estimate of $2.00 million. As a group, research analysts predict that FibroGen, Inc. will post -0.8 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of FibroGen in a report on Tuesday, May 13th. William Blair reiterated a “market perform” rating on shares of FibroGen in a report on Tuesday, April 1st. Finally, Wall Street Zen initiated coverage on FibroGen in a research note on Saturday, May 17th. They set a “hold” rating on the stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.